StockIQpro
NASDAQ:INO

Inovio Pharmaceuticals, Inc.

Track all markets on TradingView
Track all markets on TradingView

Inovio Pharmaceuticals, Inc.'s revenue fell 70.0% in fiscal 2025 to $65,343 while operating margin fell to −132871.3%, its lowest in 10 years. Free cash flow was −$88.9M, −136074.5% of revenue, and the diluted share count rose 72.6%.Summary generated from Inovio Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$65,343
Revenue growth−70.0%
Revenue, 5-yr CAGR−61.2%
Gross marginn/a
Operating margin−132871.3%
Net margin−130000.0%
ROICn/a
Return on equity−183.5%
Debt / equityn/a
Free cash flow−$88.9M
FCF margin−136074.5%
Share count change+72.6%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue210100
Operating income−301−268−144−112−87
Net income−304−280−135−107−85
Free cash flow−217−217−125−105−89

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations